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Background: Tyrosine kinase receptor family is involved in tumor growth, pathological angiogenesis and the 
progression (metastasis) of cancer. Sunitinib (Sutent®) inhibits members of the tyrosine kinase receptor family 
affecting the induction of angiogenesis and tumor progression. It is not clear if sunitinib increases the risk of 
osteonecrosis of the jaws (ONJ). The aim of this study was to carry out a systematic review about ONJ related to 
sunitinib, describing existing cases and possible associated risk factors. 
Material and Methods: The PubMed/MEDLINE and Cochrane Library databases were searched without date re-
striction up to September 2018. We included prospective and retrospective observational studies, cross-sectional 
studies, clinical cases and series of cases, involving only human subjects. The methodological quality of the stud-
ies was assessed using The Joanna Briggs Institute (JBI) and Newcastle-Ottawa tools. 
Results: A total of 13 studies fulfilled our inclusion criteria of which 7 were clinical cases, 5 case series and a 
retrospective study. All the articles were published between 2009 and 2018. Of the 102 patients treated with suni-
tinib analyzed in this study, 58 developed ONJ, being or having been treated with sunitinib and bisphosphonates 
or exclusively with sunitinib. 
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Introduction
Medication-related osteonecrosis of the jaws (MRONJ) 
is a chronic osteomyelitis-type of slow and torpid evo-
lution with the presence of one or several bone expo-
sures, without healing for at least 8 weeks, described 
with relative frequency in patients who have suffered 
cancer or bone related diseases and have been treated 
with antiresorptive drugs. According to the current con-
sensus, the clinic and the medical history are enough to 
establish the diagnosis. There are different risk factors 
associated with MRONJ. The American Association of 
Oral and Maxillofacial Surgeons (AAOMS) considers 
those related to medication (potency of the drug, dura-
tion of treatment), local factors (extractions, implants, 
periodontal surgery, tori, and trauma), demographic and 
systemic factors (advanced age, tobacco and concomi-
tant treatment with corticosteroids and chemotherapeu-
tic agents) and genetic factors (1). 
The first cases of MRONJ that showed an association 
between bisphosphonates and ONJ date from 2003 (2). 
So far, ONJ associated with bisphosphonates has been 
studied in depth. However, the relationship between 
ONJ with antiresorptive drugs such as RANKL inhibi-
tors (denosumab) and other oncological drugs such as 
bevacizumab and sunitinib is being studied at the pres-
ent time (1). 
Tyrosine kinase receptor family is involved in tumor 
growth, pathological angiogenesis and the progres-
sion (metastasis) of cancer. Sunitinib (Sutent®) inhibits 
members of the tyrosine kinase receptor family includ-
ing platelet-derived growth receptors (PDGFRD and 
PDGFRE), vascular endothelial growth factors (VEG-
FR1, VEGFR2 and VEGFR3), stem cell factor recep-
tor (KIT), tyrosine kinase type 3 (FLT3), the colony 
stimulating factor 1R (CSF-1R) and the neurotrophic 
factor receptor derived from the glial cell line (RET) 
(3,4). By inhibition of this signaling pathway, sunitinib 
affects the induction of angiogenesis and tumor pro-
gression. It was introduced for the first time in the US 
in 2006 in order to treat renal cell carcinoma, as well as 
gastrointestinal, pulmonary, thyroid and hematological 
tumors (3,5). Different studies have demonstrated its ef-
ficacy, showing remarkable delays in the progression of 
the disease and a significant benefit in overall survival 
(6). The first cases of ONJ related to sunitinib date from 
2010, when 27 cases of ONJ were described in 100,000 
Conclusions: In this systematic review, we found an increase of ONJ in patients who are medicated with other drugs 
different than bisphosphonates and denosumab. It is necessary that dentists, oral and maxillofacial surgeons as well 
as oncologists know the risk of ONJ that these antiresorptive drugs could have. There is a need to continue research-
ing in this field with the aim of an increasing knowledge in this area and creating an adequate protocol of action for 
this population.
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patients treated with this drug, in the period between 
January and November 2010 in the United Kingdom (7).
However, it is not clear if sunitinib is a causal agent of 
MRONJ. The cases described are not so numerous as in 
the case of bisphosphonates. It is believed that sunitinib 
causes ONJ because it slow down bone remodeling and 
antagonizes the process of mucosal healing by inhibit-
ing surrounding fibroblasts and endothelial cells, caus-
ing bone exposure after dental treatment (8). Other au-
thors suggest that the reduction of angiogenesis caused 
by sunitinib may impair the host’s defenses against in-
fection, which increases the risk of necrosis (9).
The objective of this work is to carry out a systematic 
review about ONJ produced by sunitinib, by describ-
ing the existing cases and the possible associated risk 
factors.
Material and Methods
This systematic review was prepared in accordance with 
the “Preferred Reporting Items for Systematic Review 
and Meta-Analysis Protocols” (PRISMA-P, 2015) (10). 
The addressed focused PECOS (population, exposure, 
comparison, and outcome) question was as follows: Do 
patients who have received or are receiving sunitinib as 
treatment for oncological processes, either exclusively 
or in combination with other drugs associated to ONJ, 
suffer from MRONJ?
As a population we consider those patients who suffer 
from oncological pathologies and receive sunitinib. The 
exposure refers to the fact these patients have been or 
are being treated with sunitinib. The risk of ONJ will be 
compared, whenever possible, between those who have 
received exclusively sunitinib and patients who have re-
ceived sunitinib in combination with bisphosphonates 
or other anti-angiogenic drugs. It will always be deter-
mined as a result that the patient has developed ONJ, 
defined according to current criteria (11).
-Eligibility Criteria
We have included 1) prospective and retrospective ob-
servational studies, cross-sectional studies, clinical cas-
es and series of cases, 2) involving only human subjects, 
3) without date restriction, 4) with full text availability, 
5) written in English and 6) published in scientific jour-
nals.
The exclusion criteria were 1) articles about ONJ in 
which patients were not receiving or had not received 
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treatment with sunitinib, 2) systematic and bibliograph-
ic reviews, letters to the editor and experimental studies 
on animals, 3) only the summary was available and 4) 
written in a language other than English.
-Information sources and search strategy
An exhaustive search of the literature was carried out, 
without restriction of date until September 24, 2018 in 
PubMed/MEDLINE and the Cochrane Library elec-
tronic databases. The keywords used were “sunitinib” 
AND “osteonecrosis” OR “osteonecrosis of the jaw” 
OR “osteonecrosis of the jaws”. Two independent re-
searchers (CV, LR) compared search results to ensure 
completeness. Duplicates were removed and the full ti-
tle and abstract of each remaining article were screened 
individually (Fig. 1). Any differences in the selection of 
eligible studies were resolved by discussion with a third 
reviewer (RMLP).
-Data collection.
Two independent reviewers (CV, LR) extracted data 
from selected articles that met inclusion criteria. Any 
disagreement was resolved with the help of a third re-
viewer (RMLP). The following information was col-
lected: 1) General characteristics of the selected studies: 
title of article, first author, year, type of study, tittle of 
the journal in which it was published, center and coun-
try where it was carried out. 2) Characteristics of the 
Fig. 1. Flow diagram of the literature search.
patients studied: number, sex, age, and illness for which 
they were taking sunitinib. 3) Data regarding sunitinib: 
dose, duration of treatment and other concomitant treat-
ments. 4) Data related to ONJ: definition, location, 
stage, triggering factors and treatment for ONJ (Table 
1, 1 continue, 1 continue-1, 1 continue-2).
-Risk of bias in individual studies 
Two independent reviewers (CV, LR) evaluated the 
methodological quality of the eligible studies. If there 
were no agreement on one paper, it was evaluated by a 
third reviewer (RMLP). For this evaluation, the critical 
tools of The Joanna Briggs Institute (JBI) (12) for case 
series and clinical cases and the Newcastle-Ottawa’s 
scale (13) for cohort studies were used. We use the JBI 
clitical appraisal tools for case reports and case series, 
according to the type of article. The bias is evaluated 
through a checklist of 8 questions for case report and 
10 questions for case series. Each question is specified 
in Table 2 and Table 3 concerning risk of bias. Finally, 
an overall appraisal is made of each article determining 
if the risk of bias is low (included), high (excluded), or 
uncertain (more information needs to be sought). We 
considered a low risk of bias if the answers “yes” were 
≥50%, high risk of bias if the answers “no” were ≥50%, 
and uncertain risk of bias if the “unclear” answers were 
≥50% (12).
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Sunitinib + other drugs ONJ 
Mahedi Mohamed 
HA et al. 
2018. 




Case series n= 1 M 
Age: 70 
RCC Dose: 50mg/day 
Duration: 9 months 
Not combined with BFs 
Location: jaw 
Time to onset: NA 
Risk factors: extraction, diabetes 
Stage: I 
Treatment: NA 
Resolution time: NA 
Asheafi F et al. 
2017. 
Department of Internal 
Medicine, 
Haematology Section, 
Isfahan University of 
Medical Sciences, 
Isfahan, Iran14.   
 
Case report n=1 M 
Age: 53 
RCC + Lung 
metastasis 
Dose: 50mg/day 
Duration: 5 months 
Not combined with BFs 
currently 
2 cycles of zoledronic acid: 4 
mg intravenously, more than 7 
months before ONJ 
 
 
Location: jaw, molar area 
Time to onset: 4 cycles of sunitinib 




- Sunitinib was discontinued  
- ATB:  oral amoxicillin 500 
mg and metronidazole 500 
mg, 7 days. 
- Rinse with chlorhexidine 
twice a day. 
Resolution time: 2 weeks after the 
interruption 





Alessandria, Italy21.  
Case series  n=44 
 
M: n= 35 
(82%) 
F: n= 9 
(18%) 
 






Duration: 1-24 months 
Combined with BFs 
Location: 
- Jaw: n= 20 
- Maxilla: n= 17 
Time to onset: NA 
Risk factors: 
- Extractions, oral 
surgery: n=12 
- Dental and periodontal 
infection: n=11 
- Spontaneous: n=8 
- Dental prostheses: n= 3 
- Implants: n=1 
Stage: NA 
Treatment: NA 
Resolution time: NA 





Denmark22.   
 



















RCC + Bone 
metastasis 
Dose: 50mg/day  
In cohort A, 15 patients 
received sunitinib as 1st line of 
tx, 2 as 2nd line of tx, and 4 as 
3rd line of tx. 6 cases of ONJ. 
In cohort B, 7 patients received 
sunitinib as 1st line of tx, 3 as 
2nd line of tx, and 5 as 3rd line 
of tx. 
In cohort C, 3 patients received 
sunitinib as 1st line of tx, 2 as 
2nd line of tx, and 2 as 3rd line 
of tx. 1 case of ONJ. 
 
Location: NA 
Time to onset: 
- Cohort A: 10,3 months of 
average (3,-17,7) 
- Cohort C: 8,2 months 





- Surgical debridement 
Resolution time: NA 






Italy15.   
 







Patient 1: RCC 
 
 
Patient 2: RCC + 
bone metastasis 
Patient 1: 
Dose: 50mg/day; Then 37,5 
mg.  
Duration: 24 months 
Combined with BFs 




Dose: 50mg/day  
Duration: 1 cycle +7 cycles 
combined with temsirolimus. 
Patient 1: 
Location: maxilla 
Time to onset: NA 
Risk factors: NA 
Stage: NA 
Treatment:  
- Surgery  
- BFs was suspended; 
Sunitinib was not suspended. 
Resolution time: 5 months later there 
was bone exposure, suppuration, and 
Table 1. Description of identified studies.
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Combined with chemotherapy 
(methotrexate, doxorubicin and 
Adriamycin, 6 cycles of 
gemcitabine and Vinorelbine, 
Roferon-A and fluorouracil). 
Combined with BFs: 
zolendroic acid 13 months, 
temsirolimus 7 cycles. 
 




Location: jaw; submandibular area 
(cutaneous fistula). 
Time to onset: NA 
Risk factors: NA 
Stage: NA 
Treatment: 
- ATB: Penicillin. 
- Antimicrobial rinses. 
- Rigid titanium plate 
(pathological mandibular 
fracture) 
Resolution time: NA. He dies from 
cancer. 
Fleissig Y et al. 
2012. 










RCC Dose: 50mg/day 
Duration: 24 months 
Not combined with BFs 
Location: jaw, molar area. 
Time to onset: during the courses of 
sunitinib 
Risk factors: No 
Stage: NA 
Treatment:  
- Sunitinib was interrupted 
- ATB intravenous 
(amoxicillin + clavulanic 
acid, hospital environment) 
- ATB penicillin-G 16 millions 
U/day, 6 weeks + amoxicillin 
orally, 6 weeks. 
Time of resolution: treatment to 3 weeks 
of treatment with ATB 
Balmor GR et al. 
2012. 
Departments of 
Medicine B, Oral and 
Maxillofacial Surgery, 
and Oncology, Sheba 
Medical Center, Tel 
Hashomer, Israel16.   
Case report n=1 M 
Age: 63 
RCC + Lung and 
bone metastasis 
Dose: 50mg/day 
Duration: 36 months 
Combined with BFs: monthly 
pamidronate 
 
Location: jaw, maxilla 
Time to onset: NA 
Risk factors: 
- Extractions 




- Sunitinib and pamidronate 
was interrupted 
- Antiseptic rinses 
- Surgical debridement 








University of Athens, 
Greece9.   
 








Patient 1: RCC 
 
Patient 2: RCC + 
Lung metastasis  
Complications by sunitinib: 
 Patient 1: 
- Oral pain 
- Halitosis 
- Persistent gingival 
bleeding (> 5 days) 
 




Time to onset: NA 
Risk factors: No 
Stage:  NA 
Treatment: 
- Metronidazole (500 mg, 
3/day, 6 days). Improved 
bleeding and pain after 2 
days. 
- Sunitinib was discontinued 
and everolimus was started 




Time to onset: NA 
Risk factors: mandibular dental 
prosthesis 
Stage:  NA 
Treatment: 
- Amoxicillin 1g 3/day 
- Chlorhexidine rinses 
- Sunitinib was discontinued. It 
was reintroduced at a dose of 
37.5mg/day + azithromycin 
3/day 
Time of resolution: NA 
 
 
Table 1 continue. Description of identified studies.
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Hoefert S et al. 
2010. 





Germany4.   












Patient 1: RCC. 
Patient 2: RCC. 








Location: jaw, molar area 
Time to onset: NA 
Risk factors: mucositis, gingivits 
Stage:  NA 
Treatment: 
- ATB orally, 29 days. 
- Sunitinib was discontinued 1 
week before surgery 
- Surgery with sequestrectomy 
- Clindamycin 300 mg iv 
3/day, 7 days, and orally 12 
days after surgery 
- 2/day mouth rinses 




Time to onset: NA 
Risk factors: mucositis, extraction 
Stage:  NA 
Treatment: 
 
- Sunitinib was discontinued 
- Surgery with sequestrectomy 
- ATB 
- Cefuroxime 500 mg 2/day 
- Mouth rinses 




Time to onset: NA 
Risk factors: extractions 
Stage:  NA 
Treatment: 
- Sunitinib was discontinued 
- Surgery  
- ATB: ampicillin 3g and 
sulbactam, intravenously 
3/day, 11 days; cefuroxime 
500 mg orally 2/day, 10 days 
Time of resolution: Sunitinib was 
resumed 28 days after the surgery, 
relapsing 5 days later. 




Castle Hill Hospital, 
Cottingham, Hull and 
East Yorkshire 
Hospitals NHS Trust, 
United Kingdom17.   
Case report  n=1 M 
Age: 51 
RCC + Bone and 
hepatic metástasis  
 
Dose: 50mg/day 
Duration: 23 months 
Combined with BFs 
(zoledronic acid) 
  
Location: jaw, molar area 
Time to onset: 4 days after the first 
administration of zoledronic acid 
Risk factors: no 
Stage:  NA 
Treatment: 
- Zoledronic acid was 
suspended 
- Sunitinib is continued 
- Oral hygiene, not smoking 
- Hyperbaric oxygen: Marx 
protocol 30/10 
Time of resolution: 
- Improvement 6 weeks after 
the start of the treatment 
- Complete healing of the 
mucosa 1 month later 
- There was no recurrence of 
ONJ during 23 months. 
Koch FP et al. 
2011. 
Oral and Maxillofacial 
Surgery, University 





Mainz, Germany17.   
Case report n=1 M 
Age: 59 
RCC + Soft tissue 
metastasis 
Dose: 50mg/day 
Duration: 1 month. 
Maintenance: 37.5mg/day 
Not combined with BFs 
Location: jaw, molar area 
Time to onset: NA 
Risk factors: extraction 
Stage: NA 
Treatment: surgery 
Time of resolution: NA. Resolution  
 
Table 1 continue-1. Description of identified studies.
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Institute of Biomedical 
Sciences (AIBS), 
Athens, Greece23.   
Retrospective. n=1 M 
Age: 48 
 
RCC + Lung and 
bone metastasis 
Dose: 50mg/day 
Combined with BFs 
(zoledronic acid, 4mg/4week) 
 
Location: jaw 
Time to onset: 28.5 months 




- Zolendronate was suspended 
- Sunitinib was continued 
- ATB 
Time of resolution: NA. Significant 
improvement 











RCC + Lung 
metastasis 
 
Dose: 37.5 mg/day 





Time to onset: 3 months after sunitinib 
Risk factors: no.  
Stage: NA 
Treatment: 
- Sunitinib was discontinued 
- ATB: Amoxicillin-clavulanic 
1g, orally, 7 days. 
Metronidazole 500 mg, 7 
days. 
- Sunitinib resumed, 3 more 
cycles à relapse. Treatment 
again. 
Time of resolution: remains of ONM 
during 5 months; improvement. 
	
	
Table 1 continue-2. Description of identified studies.
F, female; M, male; MA, mean age; SD: standard desviation; RCC, renal cell cancer; BFs, bisphosphonates; TKI, tyrosine kinase inhibitor; 
Cohort A, treatment of sunitinib and zolendronic acid to prevent skeletal complications without prior dental examination; Cohort B, treatment 
of sunitinib and zolendronic acid to reduce hypercalcemia without prior dental examination; Cohort C, treatment of sunitinib and zolendronic 
acid with previous dental examination; tx, treatment; ATB, antibiotic; NA, not available.














Were patient’s demographic 
characteristics clearly 
described?
Yes Yes Yes Yes Yes Yes Yes
Was the patient’s history 
clearly described and 
presented as a timeline?
Yes Yes Yes Yes Yes Yes Yes
Was the current clinical 
condition of the patient on 
presentation clearly 
described?
Yes Yes Yes Yes Yes Yes Yes
Were diagnostic tests or 
assessment methods and the 
results clearly described?
Yes Yes Yes Yes Yes Yes Yes
Was the intervention(s) or 
treatment procedure(s) clearly 
described?
Yes Yes Yes Yes No Yes Yes
Was the post-intervention 
clinical condition clearly 
described?
Yes No Yes No No Yes Yes
Were adverse events (harms) 
or unanticipated events
 identified and described?
Yes Yes Yes Yes Yes Yes Yes
Does the case report provide 
takeaway lessons?
Yes Yes Yes Yes Yes Yes Yes
Overall appraisal Included Included Included Included Included Included Included
Table 2. Risk of bias for case reports.











Hoefert et al. 
2010
Were there clear criteria for
 inclusion in the case series?
Yes Yes Yes No No 
Was the condition measured in 
a standard, reliable way for all 
participants included in the case 
series?
Yes Yes Yes Yes Yes
Were valid methods used for
 identification of the condition for 
all participants included in the 
case series?
Yes Yes Yes Yes Yes
Did the case series have 
consecutive inclusion of 
participants?
Yes Yes Unclear Unclear Unclear 
Did the case series have complete 
inclusion of participants?
Unclear Unclear Unclear Unclear Unclear
Was there clear reporting of the 
demographics of the participants 
in the study?
Yes Yes Yes Yes Yes
Was there clear reporting of 
clinical information of the 
participants?
Yes Yes Yes Yes Yes
Were the outcomes or follow up 
results of cases clearly reported?
Yes Yes Yes Yes Yes
Was there clear reporting of the 
presenting site(s)/clinic(s) 
demographic information?
Yes Yes Yes Yes Yes
Was statistical analysis 
appropriate?
Unclear Yes Yes Unclear Unclear
Overall appraisal Included Included Included Included Included
Table 3. Risk of bias for case series.
We used Newcastle-Ottawa’s scale to assess the risk 
of bias of the included retrospective study. The bias is 
evaluated through a questionnaire divided into 3 sec-
tions. The first one is “Selection” and it has 4 items. The 
second section is called “Comparability” and it has only 
2 items about the comparability of cohorts on the design 
or analysis. The last section is “Outcomes” and it has 3 
items about the assessment of outcome and follow-up. 
Each question is specified in Table 4. We considered a 
low risk of bias if the study had ≥ 5 of the stars (13). This 
Newcastle-Ottawa’s scale is shown in Table 4. 
-Risk of bias across studies
Graphs were made to evaluate the risk of bias of all the 
studies, grouping them according to the type of study. 
In this way, the risk of bias of the included articles was 
evaluated jointly, paying attention to the different ques-
tions posed by the JBI (Figs 2,3). No graph was shown 
for cohort studies because it was only one study.
Results
-Study selection 
The search strategy yielded 33 results, without duplicates. 
The two independent researchers (CV, LR) reviewed all 
the titles and abstracts of the 33 articles. Seven articles 
were excluded: 2 papers due to language (French, Hun-
garian), 3 articles for not being related to sunitinib and 2 
for being bibliographic reviews. (Annex 1).
After reading the full text, another 13 articles were 
excluded: 5 for being bibliographic reviews, 4 for not 
treating sunitinib, 3 for not explicitly describing the 
medication that patients took (not being able to obtain 
the number of patients medicated with sunitinib), and 
one for being a warning about the side effects of bevaci-
zumab and sunitinib (Annex 1). Finally, 13 papers were 
included in the systematic review (Fig. 1).
-Study characteristics
Of the total number of studies included in this systematic 
review, we found 7 case reports, 5 case series and a retro-
spective study. All the articles were published in the last 
decade, between the years 2009 and 2018. The studies have 
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Christodoulou et al. 
2009
SELECTION
·	 Representativeness of the exposed cohort
·	 Selection of the non-exposed cohort                    
·	 Ascertainment of exposure







·	 Study controls for bisphosphonates and antiangiogenic therapy




Assessment of outcome  
Was follow-up long enough for outcomes to occur?




Table 4. Risk of bias for retrospective studies.
Fig. 2. Risk of bias across studies for case reports.
been carried out in different countries: Italy, United King-
dom, Denmark, Greece, Germany, Israel and Iran. They 
were published in journals of different medical specialties 
among which are oral medicine, oral and maxillofacial 
surgery, oncology, urology, pharmacology and rheumatol-
ogy. All the studies included a total of 102 patients treated 
with sunitinib, of which 59 developed MRONJ. The char-
acteristics of the patients studied and the data relative to 
sunitinib and ONJ are shown in Table 1.
-Risk of bias of the studies individually
Following the criteria provided by the JBI (12) and 
Newcastle-Ottawa (13) quality assessment scales, the 
risk of bias in the studies was assessed. As shown in 
Table 2, the case reports provided by Ashrafi et al. (14), 
Agrillo et al. (15), Fleissig et al. (7), Balmor et al. (16), 
Bozas et al. (17), Koch et al. (18) y Brunello et al. (19) 
have a low risk of bias.
Table 3 shows the series of cases carried out by Mahedi 
Mohamed et al. (20), Fusco et al. (21), Smidt-Hansen et 
al. (22), Nicolatou-Galitis et al. (9) and Hoefert et al. (4) 
that presented a low risk of bias.
In the same way, following the criteria provided by the 
Newcastle-Ottawa ś scale, the retrospective study com-
pleted by Christodoulou et al. (23) had a low risk of 
bias, obtaining a good score (8 stars) (Table 4).
-Results of individual studies (Table 1)
Of the 102 patients treated with sunitinib analyzed in 
this study, we can observe that 23 (22.54%) were wom-
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Fig. 3. Risk of bias across studies for case series.
en and 77 (75.49%) were men. Data from 2 (1.96%) pa-
tients were not available (5). Regarding age, the aver-
age age was 57 years (minimum-maximum 19-70). Of 
these patients 58 (56.86%) developed ONJ, of which 38 
were males (66%), 11 females (19%) and 9 cases did not 
specify sex (15%). The average age of the patients with 
ONJ was 56 years. 
Most patients received other medications that alter bone 
remodeling such as bisphosphonates or denosumab in 
addition to sunitinib. Forty-nine patients (84%) with 
ONJ were under concomitant treatment with sunitinib 
and bisphosphonates, 5 patients (9%) were treated ex-
clusively with sunitinib, one patient (2%) had previ-
ously received bisphosphonates although at present he 
was not treated with them, and another patient (2%) was 
under combined treatment with sunitinib, bisphospho-
nates and chemotherapy.
Regarding the local risk factors, the authors highlight 
extractions and dentoalveolar surgery (n=17, 29%), fol-
lowed by dental or periodontal infections (n=11, 19%), 
mucositis due to chemotherapy (n=3, 5%), use of remov-
able dentures (n=3, 5%) or implant insertion (n=1, 2%). 
In 8 cases the ONJ was spontaneous (14%) and in 15 
cases (26%) the associated risk factors were not speci-
fied. 
Patients received sunitinib orally, and the duration of the 
treatment ranged from 1 to 36 months. Most of the patients 
with ONJ received sunitinib at a dose of 50 mg/day (91%), 
4% at a dose of 37.5 mg/day and 2% received first 50 mg/
day and were subsequently maintained at a dose of 37.5 
mg/day. Doses of 2 patients were not available (3%) (9).
Regarding ONJ location, 8 cases (13%) did not specify 
the location and in the remaining cases 34 occurred in 
the mandible (54%) and 21 in the maxilla (33%). Only 
in two cases was the stage specified at the time of diag-
nosis, being stage I (14,20). 
With regards to the treatment, 26% of the subjects with 
ONJ received antibiotic therapy, chlorhexidine mouth-
washes were recommended in 18% of cases and surgery 
was performed in 16% of cases. The authors proceed-
ed to suspend sunitinib in 18% of the cases, while the 
bisphosphonates were suspended in 16%. In the 3% of 
patients sunitinib dose was reduced from 50 mg/day to 
37.5 mg/day, and in 3% hyperbaric oxygen therapy was 
used. 
Analyzing the improvement, it was only evaluated in 
four cases (8,14,17,19). In the first case, improvement 
was observed 2 weeks after the interruption of suni-
tinib, and in another case 3 weeks after the interruption 
of sunitinib. The third patient improved after 6 weeks 
after stopping the bisphosphonate, while continuing 
with sunitinib. In the last case, improvement was ob-
served, although with the presence of ONJ remnants, 5 
months after the suspension of sunitinib.
-Risk of bias across studies
In Figure 2, it can be observed that in case reports 
most of the studies have a low risk of bias. Only in the 
question “Was the post-intervention clinical condition 
clearly described?” 15% corresponded to a high risk of 
bias, and in the question “Were adverse events (harm) 
or incapacitated events identified and described?” 30% 
had a high risk of bias.
Figure 3 shows the risk of global bias of case series. 
All the articles have an uncertain risk in the question 
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“Did the case series have complete inclusion of partici-
pants?”. Approximately 50% of the articles have had 
an uncertain risk of bias in the questions “Did the case 
series have consecutive inclusion of participants?”, and 
“Was the statistical analysis appropriate?”. In addition, 
we have considered that 30% of the studies have a high 
risk of bias in the question “Were there clear criteria for 
inclusion in the case series?”.
It was not possible to generate a figure for the retro-
spective studies, because there was only one study with 
these characteristics. Furthermore, it was not possible 
perform a meta-analysis due to the quality of the in-




The introduction of different antiangiogenic drugs such 
as sunitinib, in the therapeutic regimen of cancer (22) has 
caused an increase of ONJ related to other drugs differ-
ent than bisphosphonates. Most patients receiving suni-
tinib are related to the treatment of renal cell carcinoma. 
This type of cancer represents approximately 2% of all 
cancers worldwide and its incidence of bone metastases 
is around 30-35% (21,24). For this reason, several drugs 
such bisphosphonates, denosumab or sunitinib are used 
for their treatment, mainly to prevent bone destruction 
and tumor growth (4,9,24). It is estimated that 16% pa-
tients with cancer treated with sunitinib, alone or in 
combination with bisphosphonates, suffer from ONJ (6). 
For this reason, the European Medicines Agency issued 
safety warnings about the risk of ONJ during treatment 
with sunitinib (6,21). Moreover, the AAOMS maintains 
that ONJ can develop in patients undergoing treatment 
with antiangiogenic agents such as sunitinib (25). How-
ever this association has not been analyzed in depth (20).
In this paper, we have analyzed studies that have shown 
the presence of ONJ in patients treated with sunitinib, 
alone or combined with bisphosphonates. Most au-
thors agree that the risk of ONJ is greater when anti-
angiogenic drugs are combined with bisphosphonates 
(3,8,14,16,21,23), others such as Ashrafi et al. maintain 
that ONJ is more related to the use of sunitinib than to 
bisphosphonates, because the side effects improve with 
the disruption of sunitinib (14). On the other hand some 
authors argue that there is not enough evidence in the 
literature about the cause-effect relationship between 
sunitinib and ONJ (26). 
-ONJ in patients receiving concomitant treatment with 
sunitinib and bisphosphonates
As we have seen, in this revision 49 from 58 (84%) 
patients with ONJ were under concomitant treatment 
with sunitinib and bisphosphonates. The retrospective 
study by Beuselinck et al. shows that the incidence of 
ONJ in patients with renal cell cancer increased up to 
10% when combined treatment with bisphosphonates 
and sunitinib were added (21). Some authors justify 
this higher risk due to the greater cumulative toxicity 
profile in patients treated with bisphosphonates and 
sunitinib, since both drugs have an antiangiogenic ef-
fect (9). However, it is remarkable that ONJ was only 
observed in patients treated with zoledronate in com-
bination with sunitinib and not with the combination of 
zoledronate with sorafenib, pazopanib, temsirolimus or 
immunotherapy based on IL-2 (22,25). This could be 
explained because sunitinib is between 10%-30% more 
potent against VEGFR and PDGF than the other drugs 
(8,16,18,21). Another reason is that this drug can also 
cause damage to the oral mucosa producing gingival in-
flammation and mucositis, delaying wound healing and 
favoring infection. This in turn would increase the risk 
of ONJ (9,14). Indeed, some authors describe cases in 
which oral mucositis preceded bone exposure (4). 
-ONJ local risk factors associated with sunitinib
It has been suggested that the local risk factors of ONJ 
associated with sunitinib are similar to those of ONJ as-
sociated with bisphosphonates. Among the dental risk 
factors, it should be noted that tooth extraction is the 
most frequent triggering event (27). But there are other 
precipitating local factors such as other types of dentoal-
veolar surgery, the continued trauma to the mucosa (such 
as that produced by a removable prosthesis), the presence 
of exostosis, oral infection, the presence of periodontitis 
and poor oral hygiene (4,9,20,25). There are authors who 
also consider tobacco as a risk factor for ONJ (17).
In our work, we have observed how the local risk fac-
tors most frequently associated with the onset of ONJ 
were tooth extraction and dentoalveolar surgery, fol-
lowed by dental or periodontal infections. Other risk 
factors were mucositis due to chemotherapy, the use of 
removable dentures or implant insertion. We found that 
14% of cases were spontaneous.
-ONJ systemic risk factors associated with sunitinib
There are also a number of systemic risk factors for ONJ, 
including the duration of administration of antiresorp-
tive drugs, the dose, the simultaneous use of antiangio-
genic and antiresorptive drugs, treatment with chemo-
therapy or concomitant corticosteroids, or diseases such 
as diabetes (16,27). Since the introduction of targeted 
therapies, the life expectancy of patients with metastatic 
renal cell cancer has tripled, but this also leads to pro-
longed exposure to treatments such as bisphosphonates 
and anti-angiogenic drugs that increase the risk of ONJ 
(9,21). Also chemotherapy can be another systemic risk 
factor. There are controversies as to whether sunitinib 
is a conventional chemotherapy treatment or not. Au-
thors such as Hoefert et al. differentiate sunitinib from 
conventional chemotherapy according to the treatment 
length. Conventional chemotherapy is given for a de-
fined period of time, but sunitinib can be maintained for 
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a longer period of time, sometimes even years, which 
also increases the risk of ONJ (4,14). There are articles 
included in this study that show how the time elapsed 
between the initiation of treatment with sunitinib and 
the appearance of ONJ varied from 7 to 9 months (4). 
In comparison with bevacizumab, Mahedi Mohamed et 
al. suggest that the duration of treatment with sunitinib 
before the onset of ONJ is longer (20).
All patients included in this study received sunitinib for 
renal cell carcinoma, with or without metastasis. The 
patients received this drug orally, and the duration of 
the treatment ranged from 1 to 36 months. Ninety-one 
per cent of the patients with ONJ received sunitinib at a 
dose of 50 mg/day. Of the cases of ONJ, only 5 patients 
(9%) received sunitinib without being associated with 
other medications that cause ONJ. As we have seen 49 
patients (84%) were administered sunitinib in combina-
tion with bisphosphonates simultaneously, with zolen-
dronic acid predominating.
-Location of ONJ with sunitinib treatment
In previous studies performed on the ONJ in patients 
medicated with bisphosphonates it was observed that 
the lesions occurred mostly in the mandible (68.1%), 
and to a lesser extent in the maxilla (27.7%) or in both 
jaws (4.2%) (27). Regarding the ONJ lesions of this 
study, 54% of cases occurred in the mandible and 33% 
in the maxilla. So it seems that the location is similar to 
the case of bisphosphonates. 
-Treatment protocol
The established protocol in a case of ONJ associated with 
sunitinib is very variable and there are discrepancies 
among the authors. There are authors who propose that 
administration of systemic antibiotics, exhaustive oral 
hygiene, the use of rinses with chlorhexidine, together 
with the temporary interruption of sunitinib can lead to 
clinical improvement of the oral lesions (9,14,16,19). The 
healing time of the soft tissues after the interruption of 
sunitinib seems to be relatively short, in some studies it is 
estimated between 2-4 weeks (4,9), however when treat-
ment is restarted ONJ relapses again (4,19). 
Other authors such as Hoefert et al. (4) suggest that 
since most of the side effects are reversible, treatment 
with sunitinib should not be stopped, although dose 
adjustment has been recommended. Agrillo et al. (15) 
also are in favor of continuing sunitinib, although rec-
ommends bisphosphonate disruption in patients under 
combining treatment. 
If we observe the included studies of this systematic re-
view, the most frequent treatments of ONJ were antibi-
otic therapy (26%) (4,8,9,14,15,19,22,23), chlorhexidine 
mouthwashes (18%) (4,9,14,15,16,22), sunitinib (18%) 
(4,8,9,14,15,16,19), and bisphosphonates suspension 
(16%) (15,16,17,23), and surgery (16%) (4,15,16,18,22). 
The improvement was only evaluated in four cases 
(7,14,15,19). In 3 of these cases improvement was ob-
served after interruption of sunitinib, but the improve-
ment time was very variable, from 2 weeks to 5 months 
(7,14,19). Interestingly the fourth patient improved 
following 6 weeks after stopping the bisphosphonate, 
while continuing with sunitinib (17). 
Prevention is the main objective of disease control (16), 
however there are no specific guidelines nowadays (4). 
Some authors such as Nicolatou-Galitis et al. advise us-
ing the same recommendations used in patients receiv-
ing bisphosphonates (9). The oral examination prior to 
treatment with sunitinib is aimed at reducing the oral 
microbial load and infection; this will reduce the degree 
of oral mucositis induced by chemotherapy, which may 
reduce the risk of developing MRONJ (9). In a study 
of patients with renal cell carcinoma and bone metas-
tases treated with zoledronic acid combining with tar-
get therapy carried out by McKay et al. (24), the ONJ 
rate was 29% and was only observed in patients treated 
with sunitinib. After the introduction of mandatory oral 
examinations before the use of these drugs, the rates 
decreased to 11% (24). This theoretically justifies the 
dental check-ups prior to treatment with sunitinib and 
other antiresorptive drugs. It is also important to per-
form periodic check-ups during treatment because oral 
changes, different to ONJ, appear in 10-50% of patients 
treated with sunitinib and include dysgeusia, xerosto-
mia, mucosal sensitivity, oral pain, gingival bleeding, 
gingivitis necrotizing and oral mucositis (4,9).  
-Limitations
Regarding the limitations of this systematic review, we 
could highlight the type and characteristics of most of 
the included studies, since case series or isolated clini-
cal cases with very low methodological quality predom-
inate. In addition, each author defined different char-
acteristics of their patients, making it difficult to unify 
the aspects that may influence the development of ONJ. 
Therefore, no meta-analysis was performed.
For this reason, there is a need to better evaluate the 
incidence of ONJ in large cohorts of patients prospec-
tively, given the increasing use of treatment with antire-
sorptive drugs, targeted therapies, antiangiogenic drugs 
and bisphosphonates in the modern era of oncology.
Conclusions
With the introduction of sunitinib as a new treatment, 
a growing number of patients with ONJ have been re-
ported, it is suggested that the antiangiogenic activity of 
the targeted agents can inhibit bone remodeling, delay 
the healing of the tissues and thus enhancing the de-
velopment of ONJ. In addition, the mucositis produced 
by this drug may also increase the risk of ONJ. Most 
authors agree on an increased risk of developing ONJ 
in those cases in which bisphosphonates and sunitinib 
are combined. 
To reduce the incidence of ONJ, a clinical examination 
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should be carried out on all patients before and periodi-
cally during treatment with these drugs. A correct oral 
situation and careful oral hygiene play a fundamental 
role in preventing this pathology.
It is necessary that dentists, oral and maxillofacial sur-
geons as well as oncologists know this relationship, in 
order to establish a protocol of periodic oral check-ups 
to reduce the risk of ONJ and make an early diagnosis.
Knowledge about the relationship between ONJ and 
new target therapies such as sunitinib is still limited. 
There are discrepancies in the protocol to be followed 
in case of ONJ, although it seems that the suspension of 
the drug improves the situation. For this reason, there is 
an imperative need to continue researching in this field.
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